Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021
Rattachement africain : nl, se, pt, fi, at, tr, lu, lv, pl, si, rs, cz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
One consequence of the ongoing coronavirus disease pandemic was the rapid development of both in-house and commercial serological assays detecting anti-SARS-CoV-2 antibodies, in an effort to reliably detect acute and past SARS-CoV-2 infections. It is crucial to evaluate the quality of these serological tests and consequently the sero-epidemiological studies that are performed with the respective tests. Here, we describe the set-up and results of a comparative study, in which a laboratory contracted by the European Centre for Disease Prevention and Control offered a centralised service to EU/EEA Member and pre-accession Member States to test representative serum specimens with known serological results, with the gold standard technique (virus neutralisation tests) to determine the presence of neutralising antibodies. Laboratories from 12 European countries shared 719 serum specimens with the contractor laboratory. We found that in-house serological tests detecting neutralising antibodies showed the highest percent agreement, both positive and negative, with the virus neutralisation test results. Despite extensive differences in virus neutralisation protocols neutralisation titres showed a strong correlation. From the commercial assays, the best positive percent agreement was found for SARS-CoV-2 IgG (sCOVG) (Siemens - Atellica IM Analyzer). Despite lower positive percent agreement of LIAISON SARS-CoV-2 TrimericS IgG kit (Diasorin Inc.), the obtained results showed relatively good correlation with neutralisation titres. The set-up of this study allowed for high comparability between laboratories and enabled laboratories that do not have the capacity or capability to perform VNTs themselves. Given the variety of in-house protocols detecting SARS-CoV-2 specific neutralising antibodies, including the virus strain, it could be of interest to select reference isolates for SARS-CoV-2 diagnostic to be made available for interested EU Member States and pre-accession countries.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021
- Date Crossref
- 01/12/2023
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Institute for Public Health and the Environment Centre for Infectious Disease Control pays non établi dans la noticeStructure de recherche
-
European Centre for Disease Prevention and Control pays non établi dans la noticeOrganisme public
-
National Institute of Health Dr. Ricardo Jorge pays non établi dans la noticeInstitution
-
Finnish Institute for Health and Welfare pays non établi dans la noticeOrganisme public
-
Austrian Agency for Health and Food Safety pays non établi dans la noticeInstitution
-
General Directorate of Forestry pays non établi dans la noticeOrganisme public
-
Laboratoire National de Santé pays non établi dans la noticeStructure de recherche
-
Riga East University Hospital pays non établi dans la noticeÉtablissement de santé
-
Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy pays non établi dans la noticeStructure de recherche
-
National Laboratory of Health pays non établi dans la noticeStructure de recherche
-
Institute of Virology pays non établi dans la noticeÉtablissement de santé
-
Public Health Institute Ostrava pays non établi dans la noticeÉtablissement de santé
Centre for Infectious Disease Control — National Institute for Public Health and the Environment, European Centre for Disease Prevention and Control et National Institute of Health Dr. Ricardo Jorge, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.